Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma

ConclusionsPatients with OR by 7 or 13  weeks had significantly longer OS than patients without, confirming that early OR is an endpoint of major importance.

Source: Cancer Immunology, Immunotherapy - February 5, 2019 Category: Cancer & Oncology Source Type: research